InspireMD (NYSE:NSPR) Earns Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of InspireMD (NYSE:NSPR) in a report issued on Tuesday, Benzinga reports. Piper Sandler currently has a $4.50 price target on the stock.

Separately, StockNews.com assumed coverage on shares of InspireMD in a research report on Sunday, September 15th. They issued a sell rating on the stock.

InspireMD Price Performance

Shares of NSPR stock opened at $2.61 on Tuesday. The firm has a market cap of $64.97 million, a P/E ratio of -3.46 and a beta of 0.90. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.85. The firm’s 50-day simple moving average is $2.77 and its 200-day simple moving average is $2.51.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. During the same period last year, the business earned ($0.24) EPS. Analysts expect that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new stake in InspireMD, Inc. (NYSE:NSPR) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned 0.13% of InspireMD at the end of the most recent quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.